Ovarian Cancer Treatment Drugs Market - By Cancer Type (Epithelial, Stromal, Germ Cell), By Treatment Type (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration (Oral, Intravenous), By End-user & Forecast, 2024 - 2032

Ovarian Cancer Treatment Drugs Market Size

Ovarian Cancer Treatment Drugs Market was valued at USD 3.5 billion in 2023 and is expected to reach USD 6.1 billion by 2032, growing at a CAGR of 6.3% over the analysis period. High incidence of ovarian cancer is a major driver for market growth. According to the World Cancer Research Fund International (WCRF), ovarian cancer ranks eighth most commonly occurring cancer in women, causing more deaths annually than any other gynecological cancer. Similarly, as per Globocan’s 2020 projections, by 2040, the number of women around the world diagnosed with ovarian cancer will rise by almost 42% to 445,721 cases. Also, the number of women dying from ovarian cancer each year is projected to increase to 313,617, an increase of over 50% from 2020. Thus, growing cases of ovarian cancer will increase the demand for treatment, thereby fostering the market growth.
 

Ovarian cancer treatment drugs refer to pharmaceutical agents designed to prevent and manage ovarian cancer. These drugs are developed to target and impede the growth of cancer cells, either by directly attacking them or by inhibiting specific biological processes essential for their proliferation. Ovarian cancer treatment drugs include chemotherapy agents, targeted therapies, hormone therapies, and immunotherapies, among others.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the ovarian cancer treatment drugs market. Disruptions in healthcare services including cancer screening, delays in clinical trials, and redirected resources towards managing the pandemic impacted drug development and patient access. Also, supply chain interruptions and economic uncertainties also contributed to market challenges. Thus, owing to aforementioned factors, the market was noted to pose a negative impact on the ovarian cancer treatment market during the pandemic period.
 

Ovarian Cancer Treatment Drugs Market Trends

• Rising diagnoses coupled with increased disease awareness, and support initiatives by several organizations is anticipated to aid in market growth. Organizations such as The International Gynecologic Cancer Society (IGCS) and the World Ovarian Cancer Coalition (WOCC) conduct awareness campaigns, disseminating information on risk factors, symptoms, screening, and prevention.
   
• Similarly, ongoing research & development activities by pharmaceutical companies aiming to develop oncology drugs including ovarian cancer drugs is expected to positively impact the market growth. For instance, Pfizer is actively advancing Enzalutamide through clinical development, currently in Phase II trials. This drug is targeted for the treatment of androgen receptor positive (AR+) ovarian cancer, epithelial ovarian cancer, and primary peritoneal or fallopian tube cancer.
   

Thus, growing pipeline drugs along with rising government support for R&D funding for cancer studies, favourable reimbursement policies, collaborative research, and strategic approaches further contribute to the market expansion.
 

Ovarian Cancer Treatment Drugs Market Analysis

Based on cancer type, the global market is segmented into epithelial ovarian cancer, stromal tumors, and germ cell tumors. The epithelial ovarian cancer is expected to lead the market, projecting the highest revenue of USD 5.1 billion by 2032.
 

• The increasing incidence of epithelial ovarian cancer, coupled with a growing awareness of early detection and diagnosis is expected to propel the demand for innovative and targeted treatment options. For instance, as per the American Cancer Society (ACS), approximately 85 to 90 percent of malignant ovarian cancers fall under the category of ovarian epithelial carcinoma. Thus, early detection of such disease is anticipated to spur the segmental growth.
   
• Further, pharmaceutical companies are actively investing in the development of drugs for epithelial ovarian cancer. As research efforts intensify and innovative drugs emerge, the market share of ovarian epithelial cancer within the ovarian cancer treatment drugs sector is poised to remain prominent.

Based on treatment type, the global market is classified into targeted therapy drugs, immunotherapy drugs, chemotherapy drugs, hormone therapy drugs, and radiation therapy. The targeted therapy drugs are further categorized as PARP inhibitors, angiogenesis inhibitors, and other targeted therapy drugs. The targeted therapy drugs segment dominated the market accounting for the largest share of 43.7% in 2023.
 

• Targeted therapies are tailored to precisely identify and combat cancer cells, minimizing harm to healthy cells and enhancing treatment effectiveness with fewer side effects.
   
• In ovarian cancer, these therapies focus on suppressing molecular targets crucial for cancer cell growth. For instance, bevacizumab, an angiogenesis inhibitor used in ovarian cancer targeted therapy, has demonstrated efficacy in reducing and decelerating the growth of advanced epithelial ovarian cancers. Thus, high efficacy of these treatment method to combat ovarian cancer is anticipated to drive the segmental growth.
   

Based on route of administration, the global market is classified into oral, intravenous, and intraperitoneal. The intravenous route of administration dominated the market and is anticipated to witness a CAGR of over 6.6%.
 

• The intravenous route has established dominance in the ovarian cancer treatment drug market, due to its efficacy and widespread acceptance. Intravenous administration ensures direct and efficient delivery of therapeutic agents into the bloodstream, allowing for rapid systemic distribution.
   
• This method is particularly advantageous in managing ovarian cancer, as it facilitates precise dosage control and immediate access to the targeted cells.
   
• Therefore, several advantages offered by this route makes it a preferred route of cancer drug administration, thereby fostering the segmental growth.
   

Based on end-user, the market is classified into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies dominated the market accounting for the largest revenue of USD 2 billion in 2023.
 

• Hospital pharmacies dominated the ovarian cancer treatment drug market due to their pivotal position in the distribution and dispensing of specialized medications. The complex nature of ovarian cancer treatments often requires close collaboration between healthcare providers and pharmacists.
   
• Hospital pharmacies handle diverse and specialized drug formulations, ensure seamless access to these critical medications. Also, high patient footfall in hospitals further contributes to the dominance of hospital pharmacies in the market.

• High incidence of ovarian cancer in the region is a major factor driving the regional market growth. For instance, according to National Cancer Institute (NCI) cancer statistics estimation, the U.S. reported 19,710 ovarian cancer diagnoses and 13,270 associated deaths, emphasizing the region's pivotal role in addressing this health challenge in 2023. Such rising ovarian cancer cases in the region is expected to surge the demand for potential treatment propelling the market growth.
   
• Further, the region's robust healthcare infrastructure and advanced medical facilities facilitate early diagnosis & ovarian cancer treatment as well as presence of key players further accelerates the regional market growth.
   

Ovarian Cancer Treatment Drugs Market Share

The market is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, extensive R&D investments, and a focus on clinical trials characterize the competitive strategies. The market is dynamic, marked by ongoing advancements, regulatory approvals, and efforts to address unmet medical needs in ovarian cancer treatment.
 

Ovarian Cancer Treatment Drugs Market Companies

Prominent players operating in the ovarian cancer treatment drugs industry are as mentioned below:

• F. Hoffmann-La Roche AG
• GlaxoSmithKline Plc.
• Immunogen Inc.
• Astrazeneca
• Merck KGaA
• Oasmia Pharmaceutical AB
• Clovis Oncology, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Eli Lilly and Company
• Aravive Biologics
• Allarity Therapeutics
   

Ovarian Cancer Treatment Drugs Industry News

• In November 2023, AbbVie Inc. entered into an agreement to acquire ImmunoGen, Inc., incorporating its leading cancer therapy, ELAHERE. This first-in-class antibody-drug conjugate (ADC) is approved for platinum-resistant ovarian cancer. The acquisition is expected to enhance AbbVie's foothold in the solid tumor sector, expediting both its commercial and clinical presence in this domain.
   
• In September 2022, AstraZeneca and Merck announced the approval of Lynparza (olaparib) in China as first-line maintenance treatment with bevacizumab for homologous recombination deficient (HRD)-positive advanced ovarian cancer. This helped the company to increase the sales of its product in China.
   

Global ovarian cancer treatment drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Cancer Type

• Epithelial ovarian cancer
• Stromal tumors
• Germ cell tumors

Market, By Treatment Type

• Targeted therapy drugs
  • PARP inhibitors
  • Angiogenesis inhibitors
  • Other targeted therapy drugs

• Immunotherapy drugs
• Chemotherapy drugs
• Hormone therapy drugs
• Radiation therapy

Market, By Route of Administration

• Oral
• Intravenous
• Intraperitoneal

Market, By End user

• Hospital pharmacies
• Retail pharmacies
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa